Azithromycin and the microbiota of cystic fibrosis sputum

BACKGROUND: Azithromycin is commonly prescribed drug for individuals with cystic fibrosis (CF), with demonstrated benefits in reducing lung function decline, exacerbation occurrence and improving nutrition. As azithromycin has antimicrobial activity against components of the uncultured microbiome an...

Descripción completa

Detalles Bibliográficos
Autores principales: Acosta, Nicole, Thornton, Christina S., Surette, Michael G., Somayaji, Ranjani, Rossi, Laura, Rabin, Harvey R., Parkins, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008652/
https://www.ncbi.nlm.nih.gov/pubmed/33784986
http://dx.doi.org/10.1186/s12866-021-02159-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008652/
https://www.ncbi.nlm.nih.gov/pubmed/33784986
http://dx.doi.org/10.1186/s12866-021-02159-5

Ejemplares similares